A Phase 2 interventional study of ONO-4538 in Rhabdoid Tumor, sponsored by Ono Pharmaceutical Co., Ltd.. Recruiting at 14 sites in Japan. Open to participants aged 1 Year and older. Per ClinicalTrials.gov, last updated 2026-08-04.
Sponsored by Ono Pharmaceutical Co., Ltd. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Investigate the efficacy and safety of ONO-4538 for the treatment of rhabdoid Tumors
115 studies on the registry are indexed under Rhabdoid Tumor; 23 are open to participants now.
This study's planned enrollment of 23 is below the median of 28 across 98 interventional studies indexed under Rhabdoid Tumor.
Browse Rhabdoid Tumor studies →Ono Pharmaceutical Co., Ltd. is the lead sponsor of 49 studies on the registry; 18 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: ONO-4538
every 2 weeks
Also known as: Nivolumab
Objective response rate (ORR)
Time frame: up to 4.5 years
Objective response rate (ORR) (site investigator assesment)
Time frame: up to 4.5 years
Overall survival (OS)
Time frame: up to 4.5 years
Progression free survival (PFS)
Time frame: up to 4.5 years
Disease control rate (DCR)
Time frame: up to 4.5 years
Time to response (TTR)
Time frame: up to 4.5 years
Best overall response (BOR)
Time frame: up to 4.5 years
Percent change from baseline in the sum of diameters of target lesions
Time frame: up to 4.5 years
Best reduction percent change from baseline in the sum of diameters of target lesions
Time frame: up to 4.5 years
Incidence of Adverse Events [Safety]
Time frame: Up to 30 days after the last dose
Plan to share: No
No publications or documents are linked to this record.
Started Nov 2024 (actual). Primary completion is estimated for Jan 2029, 50 months after the start.
Of 23 phase 2 interventional studies under Rhabdoid Tumor, half reached primary completion within 63 months of starting (the median), counting those still running; a quarter within 52 and three quarters within 89. This study's planned 50 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nivolumab
Ono Pharmaceutical Co., Ltd. →